VRX Share Price

Open 17.99 Change Price %
High 18.04 1 Day -0.60 -3.34
Low 17.16 1 Week -1.00 -5.45
Close 17.36 1 Month 5.10 41.60
Volume 993226 1 Year -17.67 -50.44
52 Week High 42.25
52 Week Low 11.20
VRX Important Levels
Resistance 2 18.18
Resistance 1 17.84
Pivot 17.52
Support 1 16.88
Support 2 16.54
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
YRI 3.75 1.90%
ONC 0.62 -32.61%
ONC 0.62 -32.61%
ECA 14.70 -2.84%
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
CUM 0.90 13.92%
CUM 0.90 13.92%
BLU 0.35 12.90%
LSG 2.08 8.33%
TSE Canada Top Losers Stocks
ONC 0.62 -32.61%
ONC 0.62 -32.61%
GBV 0.46 -24.59%
MNR 0.17 -15.00%
MNR 0.17 -15.00%
CTU-A 0.19 -9.52%
BAA 0.10 -9.09%
BAA 0.10 -9.09%
EXN 1.40 -8.50%
PNP 2.40 -8.05%

Valeant Pharmaceuticals (TSE: VRX)

VRX Technical Analysis 1.5
As on 24th May 2017 VRX Share Price closed @ 17.36 and we RECOMMEND Sell for LONG-TERM with Stoploss of 23.86 & Buy for SHORT-TERM with Stoploss of 14.64 we also expect STOCK to react on Following IMPORTANT LEVELS.
VRX Target for May
1st Target up-side 14.61
2nd Target up-side 15.99
3rd Target up-side 17.36
1st Target down-side 10.69
2nd Target down-side 9.31
3rd Target down-side 7.94
VRX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.valeant.com
VRX Address
2150 St. Elz
Laval, QC H7L 4A8
Phone: 514-744-6792
Fax: 514-744-6272
VRX Latest News
Valeant: Substantially Undervalued   Seeking Alpha   - 24th May 17
Home Health Care Valeant Pharmaceuticals Intl Inc (NYSE:VRX) And Actavis Make ...   Journal Transcript   - 24th May 17
Valeant: A Valuation Check   Seeking Alpha   - 24th May 17
Take Profits Now in Valeant Pharmaceuticals Intl Inc (VRX) Stock   Investorplace.com   - 23rd May 17
Valeant: Et Tu Mylan?   Seeking Alpha   - 20th May 17
4 Arguments Against The Valeant Bear Case   Seeking Alpha   - 18th May 17
Valeant's Revenue Growth Is At Risk   Seeking Alpha   - 18th May 17
Valeant: Overbought And Overvalued   Seeking Alpha   - 16th May 17
5 More Reasons Valeant Pharmaceuticals Bottomed   Seeking Alpha   - 15th May 17
Valeant Pharmaceuticals International Inc swings to first profit in 6 quarters ...   Financial Post   - 09th May 17
Interactive Technical Analysis Chart Valeant Pharmaceuticals ( VRX TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Valeant Pharmaceuticals
VRX Business Profile
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.